These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17351724)

  • 21. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

  • 22. Current therapy of multiple sclerosis.
    Johnson KP; Baringer JR
    Hosp Pract (1995); 2001 Apr; 36(4):21-2, 25-8; discussion 28-9. PubMed ID: 11327342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 25. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 27. Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis.
    Midgard R; Ertresvåg K; Trondsen E; Spigset O
    Neurology; 2005 Jul; 65(1):170-1. PubMed ID: 16009917
    [No Abstract]   [Full Text] [Related]  

  • 28. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
    Schmidt S; Schneider T; Schmidt-Wolf I; Ko Y; Schlegel U; Klockgether T; Hertfelder HJ
    Mult Scler; 2004 Apr; 10(2):243-4. PubMed ID: 15124772
    [No Abstract]   [Full Text] [Related]  

  • 29. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
    Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
    J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT
    Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
    Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depressive symptoms in a treated multiple sclerosis cohort.
    Patten SB; Fridhandler S; Beck CA; Metz LM
    Mult Scler; 2003 Dec; 9(6):616-20. PubMed ID: 14664476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 34. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 35. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
    Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
    Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 39. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
    Hwang L; Orengo I
    Cutis; 2001 Oct; 68(4):287-8. PubMed ID: 11710450
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
    Byrnes V; Afdhal N; Challies T; Greenstein PE
    Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.